Galen Limited
Seagoe Industrial Estate
Craigavon
BT63 5UA
United Kingdom

Tel: +44 (0) 28 3833 4974
E-mail: customer.services@galen-pharma.com
Email: info@galen-pharma.com
Web: www.galen-pharma.com

Methodological Note: Reporting transfers of value to patient organisations, patients, journalists and members of the public during 2024 for reporting in 2025.

Introduction

Galen is a privately-owned global pharmaceutical company headquartered in Craigavon, Northern Ireland. Specialising in both branded generics and speciality products.

As a UK-based company, Galen is fully committed to adhering to The Association of the British Pharmaceutical Industry (ABPI) Code of Practice. These codes require pharmaceutical companies to publicly disclose transfers of value made directly or indirectly to healthcare professionals (HCPs) and healthcare organisations (HCOs) located in Europe. In addition to disclosure payments for HCPs and HCOs, Galen are also required to disclose payments made to Patient Organisations as well as members of the public, including patients and journalists. This disclosure will be made via the Galen website.

With regards to Galen's disclosure of payments for 2024, details of the methodology used are listed below.

Details of what is disclosed

Patient Organisation Disclosure: Companies must make publicly available annually, a list of patient organisations to which it provides donations, grants or sponsorship (including in relation to events/meetings) or with whom it has engaged to provide contracted services over the reporting period. This information must be disclosed on the company website either on a national or European level. Each reporting period shall cover a full calendar year. Each company must include a note of methodologies used by it in preparing the disclosures and identifying support and contracted services provided.

Galen have disclosed information for 1 patient organisation during the timeframe. This is relating to sponsorship of events/meetings.

Members of the Public (Including patients & journalists) Disclosure: Companies must make publicly available annually details of the fees for certain contracted services paid to members of the UK public, including patients and journalists. These services include speaking at meetings, assistance with training, writing articles and/or publications, participating in advisory boards, advising on the design etc of clinical trials and participating in market research where such participation involves remuneration and/or travel

Galen have disclosed 2 transfers of value to members of the public. This includes fees for 5 patients and 3 members of the public.

Scope

This disclosure includes all transfer of values made to patient organisations, patients, journalists and members of the public based in Europe, Great Britain, Northern Ireland, and the Republic of Ireland during 2024. It includes a description of the nature of the support or services provided.

Direct payments made by Galen Limited use the date the transaction was paid. A transfer of value is made when the payment is complete.

Other Information

VAT: Galen does not place VAT on the amounts disclosed.

Currency Aspects: Galen has provided all payments in GBP (£) – in instances where payments were made to HCPs requiring payment in Euros (€) Galen has made the payment in euros via our company account. Standard conversion rates to GBP were applied to any other currencies at the time of activity and have been disclosed as such.